NY-AQARA
Aqara, a leading provider of smart home solutions, is thrilled to announce the expansion of its smart lighting product line with the introduction of the Ceiling Light T1M. This smart light fixture seamlessly blends radiant white lights with a colorful gradient ring for everyday and atmospheric illumination. The Ceiling Light T1M is available on Aqara’s Amazon brand stores in North America (US, Canada) and Europe (France, Germany, Italy, Poland, Spain, UK) as well as through select Aqara retailers worldwide*.
Designed for rooms ranging from 5 to 20 square meters (approximately 54 to 215 square feet), this ceiling light offers a versatile lighting solution. With a spectrum ranging from warm-to-cool whites (2700-6500K) to an impressive 16 million colors, users can effortlessly create the perfect ambiance for any mood or occasion. Moreover, its independently addressable RGB ring enables seamless integration into holistic smart home experiences, allowing users to visually receive notifications or alerts regarding their home’s status changes, such as when someone rings the Aqara doorbell or triggers an armed security system. For hearing-impaired individuals, the T1M Ceiling Light can be paired with smart security alarm systems to add customized visual alerts, further enhancing the safety and convenience for users.
Similar to other Aqara Zigbee devices, the Ceiling Light T1M supports Matter and other major platforms, such as Apple Home (including Adaptive Lighting for HomeKit users), Amazon Alexa, and Google Home, via a compatible Aqara hub*. The wide compatibility positions it as a future-proof addition to any space. The ceiling light features low idle power consumption thanks to the energy-efficient Zigbee protocol, while also serving as a repeater of the Zigbee network, enhancing network range and responsiveness. Zigbee also ensures local automation to remain functional even when the ceiling light is disconnected from the internet. Engineered for excellence, the T1M features a Color Rendering Index (Ra) of 90 for true-to-life hues and has undergone rigorous testing to ensure a lifespan of 50,000 hours for longevity.
Expanding upon the success of the LED Strip T1, the Ceiling Light T1M represents the latest addition to Aqara's smart light portfolio, furthering the Company's commitment to creating the ultimate smart home experience. With smart light being an integral part of a truly smart home, the T1M harmonizes with other Aqara devices to elevate everyday living. For example, the T1M can be paired with presence or motion sensors for automated illumination, which helps cut energy waste. Moreover, by coupling it with an Aqara light switch, which features Wireless Switch mode, users can enjoy the familiarity of traditional light control while preserving the sophistication of the Ceiling Light's smart functionality.
For more information on the Ceiling Light T1M, please visit our website.
* Product availability may vary among different retail channels and could be updated on an ongoing basis. It’s recommended to check with the regional retailer(s) for real-time availability.
** The Matter compatibility of the Ceiling Light T1M requires a Matter-compatible Aqara hub (e.g., Hub M2, Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3) and may be in Beta by the time of its launch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229437381/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom